VTR Ventas Inc.

Ventas to Participate in NAREIT REITWeek 2017 Conference

Ventas, Inc. (NYSE: VTR) announced today that management will make a presentation regarding the Company at the NAREIT REITWeek 2017 Conference (the “NAREIT Conference”) in New York, New York on June 7, 2017 at 11:45 a.m. Eastern Time.

The presentation will be audio webcast and may accessed through the Company’s website at www.ventasreit.com/investor-relations. Any Company written materials accompanying the presentation or the Company’s meetings with certain investors at the NAREIT Conference will be available on the Company’s website starting at 8 a.m. Eastern Time on June 6. The webcast and any written materials will be archived at www.ventasreit.com/investor-relations for a limited period following the event.

Ventas, Inc., an S&P 500 company, is a leading real estate investment trust. Its diverse portfolio of approximately 1,300 assets in the United States, Canada and the United Kingdom consists of seniors housing communities, medical office buildings, life science and innovation centers, inpatient rehabilitation and long-term acute care facilities, general acute care hospitals and skilled nursing facilities. Through its Lillibridge subsidiary, Ventas provides management, leasing, marketing, facility development and advisory services to highly rated hospitals and health systems throughout the United States. References to “Ventas” or the “Company” mean Ventas, Inc. and its consolidated subsidiaries unless otherwise expressly noted.

Click here to subscribe to Mobile Alerts for Ventas, Inc.

EN
06/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ventas Inc.

Ventas Inc: 1 director

A director at Ventas Inc sold 23,500 shares at 64.232USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch